Clinical Trial Update: Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting the effects of ticagrelor on preventing cardiovascular events in patients with prior myocardial infarction, compared with placebo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Myocardial Infarction
• Stroke

Drugs mentioned

• BRILINTA (ticagrelor)

Snippet

Sponsor: AstraZeneca | Conditions: Myocardial Infarction, Cardiovascular Death | Phase 3 | Status: COMPLETED | Results posted: 2015-12-09